Caprolactam Chemicals (CAPRO) Reports Near-Total Revenue Collapse in Q2 FY27
The commodity chemicals maker saw revenue plunge 94% year-on-year to just ₹0.14 crore, with losses widening as fixed costs overwhelmed a near-standstill operation.
Caprolactam Chemicals' Q2 FY27 results show a company in severe distress. Revenue collapsed 94% year-on-year to ₹0.14 crore, while the net loss widened to ₹1.2 crore as interest and depreciation costs exceeded total income.
For a commodity chemicals business, generating revenue is the fundamental test. Caprolactam Chemicals failed that test spectacularly in the September quarter, with sales nearly vanishing and losses mounting under the weight of unavoidable costs.
The numbers tell a story of operational paralysis. Revenue collapsed to ₹0.14 crore, down 94% from a year ago and 70% from the already weak June quarter. The net loss widened to ₹1.2 crore. A glance at the recent trend shows how abruptly the business has fallen off a cliff.
Revenue & profit
Revenue (₹ Cr)
Profit (₹ Cr)
Metric
CurrentQ2 FY27
PreviousQ1 FY27
Same quarter LYQ2 FY26
Revenue (₹ Cr)
0.14YoY -94%
0.47
2.36
Profit (₹ Cr)
-1.20YoY -1023%
-0.99
0.13
The Burden of Fixed Costs
A 41% cut in total expenses was not enough to prevent disaster. The problem, as noted by MarketsMojo, is that revenue fell faster than the company could shrink its cost base. Interest and depreciation alone totalled ₹0.62 crore, far exceeding the quarter's total income.
In fact, ScanX Trade reported that finance costs of ₹0.21 crore were higher than the entire quarter's revenue. This misalignment between a near-zero top line and sticky fixed costs created an unsustainable cash burn.
A Sector Outperformer's Struggle
The crisis appears company-specific. While the broader commodity chemicals sector has faced challenges, peer GSFC reported a 30% growth in its industrial products segment for the same quarter, according to Indian Chemical News. Caprolactam's near-total shutdown suggests deeper operational or demand issues within its own business model.
The Market's Verdict
Investor sentiment has turned decisively negative. MarketsMoji downgraded the stock to a 'Strong Sell' with a score of 23/100 ahead of the results, citing deteriorating fundamentals. The stock trades at a significant premium to the sector despite these troubles, with a TTM P/E of 51.7 against an industry average of 37.3.
Institutional investors are entirely absent, holding 0% of the company. Promoter holding remains stable at 54.5%, but with no fresh capital infusion announced, the path to stabilisation is unclear.
Key Points
Revenue fell 94% year-on-year to ₹0.14 crore, indicating a near-complete halt in business activity.
The net loss widened to ₹1.2 crore as fixed interest and depreciation costs overwhelmed the minimal income.
The company's challenges are idiosyncratic, occurring even as larger peers in the chemical space report growth.
With zero institutional ownership and a 'Strong Sell' analyst rating, market confidence has evaporated.
“
Hexa Perspective
This quarter moves beyond cyclical weakness into existential territory. Generating less than 6% of the year-ago revenue while carrying full fixed costs is a recipe for rapid equity erosion. The trailing-twelve-month net profit margin is already deep in negative territory at -14.7%.
The immediate question is not about growth but survival. Can the company secure new orders or contracts to restart revenue generation before its liquidity cushion is exhausted? The next quarter's results will be critical in determining whether this was a catastrophic aberration or the beginning of a terminal decline. Without a visible operational turnaround, the current valuation premium seems untenable.
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.
Frequently asked questions
What were Caprolactam Chemicals' Q2 FY27 results?
Caprolactam Chemicals reported a net loss of ₹1.20 crore for Q2 FY27 (September 2026 quarter), a severe reversal from a profit of ₹0.13 crore in Q2 FY26. Revenue from operations collapsed by 94% year-on-year to just ₹0.14 crore, indicating a near-total halt in business activity.
Why did Caprolactam Chemicals' revenue collapse by 94% in Q2 FY27?
Caprolactam Chemicals' revenue collapsed due to what appears to be a severe operational disruption or a complete loss of customer orders. Reports from MarketsMojo suggest the sequential 70% drop from Q1 indicates challenges intensified, bringing business activity to a near standstill.
Did Caprolactam Chemicals experience a complete shutdown in Q2 FY27?
Analysis from MarketsMojo suggests the 94% year-on-year revenue collapse to ₹0.14 crore indicates a near-complete operational shutdown. The company generated less than 6% of its year-ago revenue while continuing to incur substantial fixed costs like interest and depreciation.
Why did Caprolactam report a ₹1.2 crore loss despite cutting expenses?
Caprolactam's 41% cut in total expenses was insufficient because revenue fell even faster. As per ScanX Trade, finance costs of ₹0.21 crore alone exceeded the quarter's total revenue of ₹0.14 crore, highlighting a fatal mismatch between income and unavoidable fixed costs.
What is Caprolactam Chemicals' debt and interest burden?
Caprolactam's interest expense rose 12% year-on-year to ₹0.21 crore. ScanX Trade notes borrowings increased to ₹12.19 crore as of September 2026. With minimal revenue, the interest burden now poses a significant threat to cash flow and sustainability.
What guidance did Caprolactam management provide for future quarters?
The company's results filing did not include specific forward guidance. External analysis from MarketsMojo states the Q3 FY27 results will be critical to determine if the Q2 collapse was an aberration or the start of a terminal decline, highlighting the absence of a near-term recovery plan.
What is the demand environment for caprolactam chemicals?
The broader market environment shows resilience. Indian Chemical News reported that peer GSFC saw a 30% sales growth in its industrial products segment in Q2 FY27, with better realizations for caprolactam. This suggests Caprolactam Chemicals' issues are company-specific, not industry-wide.
What were analyst estimates for Caprolactam Q2 FY27?
While specific consensus estimates are not cited, the market's reaction was decisively negative. MarketsMojo downgraded the stock to a 'Strong Sell' rating ahead of the results, indicating performance was significantly worse than any reasonable expectation.
Which brokerages changed their rating after Q2 results?
MarketsMoji downgraded Caprolactam Chemicals from 'Sell' to 'Strong Sell' on November 3, 2026, citing deteriorating technicals and weak financials. The firm's overall Mojo Score is a very low 23 out of 100, reflecting deep scepticism.
Are institutional investors changing their stake in Caprolactam?
Institutional investors have zero stake in Caprolactam Chemicals. Data from MarketsMojo shows FII, mutual fund, and insurance holdings are all at 0.00%, a situation unchanged for several quarters, reflecting the stock's micro-cap status and perceived high risk.
Caprolactam Chemicals Q2 FY27 results August 2026
Caprolactam Chemicals announced its Q2 FY27 (September 2026 quarter) results on November 14, 2026. The company reported a net loss of ₹1.20 crore, a drastic fall from a ₹0.13 crore profit a year ago, as revenue collapsed 94% to just ₹0.14 crore.
Caprolactam Chemicals Q2 net profit
Caprolactam Chemicals reported a net loss of ₹1.20 crore for Q2 FY27, a severe deterioration from a net profit of ₹0.13 crore in the same quarter last year (Q2 FY26). The result was driven by a near-total collapse in revenue to ₹0.14 crore.
